C4X3256 (Rocavorexant): First Scale-Up Campaign for a Selective Orexin-1 Receptor Antagonist — Process Intelligence Dossier
De-risking an in-licensed route: Indivior and Almac's convergent 10-stage, 29.2 kg scale-up of the selective orexin-1 antagonist C4X3256 (rocavorexant), with T3P replacing the acid-chloride endgame.
Read article →